Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics

Study Overview
=================
Brief Summary
-----------------
Head trauma is a common injury in emergency department. Investigation to search for complication is guided by the clinical examination and the case history, such as taking anti-thrombotics. Cranial computed tomography (CCT) is the gold standard to investigate, and is mandatory in case of antithrombotic drugs. Recently, some biomarkers have proven their utility to rule-out mild head trauma without CCT in the general population. Among these biomarkers, S100β protein has been added in guidelines for mild head trauma. Some studies have found similar data in population taking anticoagulant or antiplatelet drugs. The investigators aim to prove medical utility of S100β protein in population under antithrombotics, by the reduction of CCT use. Then, The investigators hypothesize that the add of S100β protein reduces cost of health care in the management of head injury in that population.

Official Title
-----------------
Intérêt de la protéine S100β Dans Les Traumatismes Crâniens légers Sous Anti-Thrombotiques

Conditions
-----------------
Mild Head Injury, Anticoagulant, Antiplatelet

Intervention / Treatment
-----------------
* Other: Dosage of S100β protein


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient ≥ 18 years old Taking antithrombotic medication (antiplatelet drugs, K vitamin antagonist, direct oral anticoagulants, heparins) Mild head trauma with Glasgow coma scale ≥ 13 Trauma occured ≤ 6 hours Agreeing the participation in the study Exclusion Criteria: Head injury occured > 6 hours Patient < 18 years old or under juridic protection pregnant women polytrauma Glasgow coma scale ≤ 12 ancient or actual cerebral ou cutaneous neoplasia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Dosage of S100β protein|Dosage of S100β protein|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic performances are evaluated by AUC | Diagnostic performances of S100β protein in case of mild head trauma for detection of traumatic intracranial lesion in patients under antithrombotic medication compare to cranial computed tomography. | 1 day | 
| Diagnostic performances are evaluated by sensibility, specificity | Diagnostic performances of S100β protein in case of mild head trauma for detection of traumatic intracranial lesion in patients under antithrombotic medication compare to cranial computed tomography. | 1 day | 
| Diagnostic performances of S100β protein in case of mild head trauma for detection of traumatic intracranial lesion in patients under antithrombotic medication compare to cranial computed tomography. | Diagnostic performances are evaluated by positive and negative predictive values between the strategy with S100β protein compared to the strategy with systematic cranial computed tomography. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mild head injury, traumatic brain injury, traumatic intracranial hemorrhage, Anticoagulant, antiplatelet, anticoagulant, antithrombotic, S100β protein, health care cost